Related Experiment Video
Updated: May 27, 2025

Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
Addressing challenges in pediatric thrombosis: a comprehensive guideline development
Yin Wang1, Qinan Yin1, Jiangting Liao1
1Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Insights
This study developed a guideline for pediatric thrombosis pharmacotherapy. It provides evidence-based recommendations for anticoagulant medications to improve treatment and prevention in children.
Area of Science:
- Pediatric Hematology
- Pharmacology
- Evidence-Based Medicine
Background:
- Pediatric thrombosis is a severe condition with increasing incidence.
- Children's unique physiology necessitates distinct treatment guidelines from adults.
- Current pharmacological management of pediatric thrombosis presents significant challenges.
Purpose of the Study:
- To conduct a systematic review of evidence-based literature for pediatric thrombosis.
- To propose pharmacological prevention and treatment recommendations for pediatric thrombotic diseases.
- To develop a practical pharmacotherapy guideline for rational medication use in children.
Main Methods:
- Followed WHO Handbook for Guideline Development, including systematic literature searches.
- Utilized the Delphi method for expert consensus on clinical issues and recommendations.
- Employed the GRADE approach to assess the quality of evidence.
Main Results:
- Collected and evaluated 29 clinical issues with 78 experts.
- Selected 13 key clinical issues through two Delphi rounds.
- Formulated 13 clinical pharmacotherapy recommendations for pediatric thrombosis.
Conclusions:
- Developed a guideline with specific anticoagulant recommendations for pediatric thrombosis.
- Aims to enhance the feasibility, safety, and standardization of pediatric thrombosis treatment.
- Promotes more effective prevention and management strategies for pediatric thrombotic diseases.
Background:
Pediatric thrombosis is a relatively rare but severe condition in the field of pediatrics, with far-reaching consequences. Recent studies have indicated a rising incidence of this disease in children over the years. Additionally, the pharmacological treatment of thrombotic diseases in children faces numerous challenges. Due to significant physiological differences between children and adults, guidelines for the prevention and treatment of thrombotic diseases in adults cannot be directly applied to pediatric patients.
Purpose:
A systematic review of the existing evidence-based medical literature should be conducted to propose pharmacological prevention and treatment recommendations for pediatric thrombotic diseases. Developing a comprehensive and practical pharmacotherapy guideline for the prevention and treatment of pediatric thrombotic diseases is essential to enhancing the rational use of medications in managing these conditions in children.
Methods:
The guideline development followed the World Health Organization's (WHO) Handbook for Guideline Development. This involves systematically searching and extensively collecting data on common medication issues in the prevention and treatment of pediatric thrombosis nationwide. The Delphi method was used to survey experts and identify the clinical issues to be included. Subsequently, a systematic literature review was conducted to evaluate existing primary studies, systematic reviews, and guidelines or consensus statements from professional organizations. The quality of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. The Delphi method was employed again to reach a consensus on the recommendations and evidence levels. This process was culminated in the development of the Guideline for Pharmacological Management of Thrombotic Diseases in Children.
Results:
During the guideline development process, a total of 29 clinical issues were collected and evaluated by 78 experts in clinical pharmacy and clinical medicine. Through two rounds of surveys, 13 clinical issues were selected. Under the supervision of two methodologists, 13 clinical pharmacotherapy recommendations were formulated.
Conclusion:
By conducting a comprehensive assessment of the feasibility and safety of clinical practices, the guideline provides specific anticoagulant medication recommendations for pediatric healthcare professionals. This will help enhance the prevention and treatment of pediatric thrombosis, promoting more standardized and effective medical practices.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pre-Procedural Guidelines for Assessing Blood Pressure
Clot Retraction and Fibrinolysis
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...

